文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE 肽受体放射性核素治疗中的胆囊显影:肝转移灶的潜在模拟者

Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE: A Potential Mimicker of Hepatic Metastases.
PubMed 文献 · Clin Nucl Med · 2020-01-01

治疗后SPECT/CT(而非治疗前或治疗后PET/CT)显示胆囊显影,提示镥-177-DOTATATE经胆汁排泄。该病例提示胆汁排泄的镥-177-DOTATATE可成为肝转移灶的罕见模拟者,SPECT/CT对精确解剖定位、避免误判具有重要作用。

要点

  • 镥-177-DOTATATE治疗后SPECT/CT可见胆囊显影,提示药物经胆汁排泄。
  • 该胆囊显影仅在治疗后SPECT/CT出现,治疗前及治疗后PET/CT均未见。
  • 胆汁排泄的镥-177-DOTATATE可模拟肝转移灶,需SPECT/CT精确解剖定位以避免误判。

核心结论

  • 胆汁排泄的镥-177-DOTATATE可能成为肝转移灶的罕见模拟者。
  • SPECT/CT对精确解剖定位、避免误判具有重要作用。

研究设计与样本

  • 本文为病例报告,对象为一名30岁男性假肌源性血管内皮瘤患者。

主要发现

  • 治疗后SPECT/CT显示胆囊显影,而治疗前及治疗后PET/CT均未见胆囊显影。
  • 治疗后SPECT/CT的胆囊显影证实镥-177-DOTATATE排泄进入胆汁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gallbladder visualization represents a rare incidental finding when using somatostatin receptor-targeted SPECT radiopharmaceuticals such as In-octreotide. We present the case of a 30-year-old man with pseudomyogenic hemangioendothelioma who underwent Ga-DOTATATE PET/CT for restaging of metastatic disease and subsequent treatment with peptide receptor radionuclide therapy with Lu-DOTATATE. Posttherapeutic SPECT/CT, but not pretherapeutic or posttherapeutic PET/CT, showed gallbladder visualization, evidencing Lu-DOTATATE excretion into the bile. This case highlights that biliary Lu-DOTATATE excretion may represent a rare mimicker of hepatic metastases and emphasizes the role SPECT/CT for precise anatomical correlation to avoid misinterpretation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Diekmann J, Werner RA, Ross TL, et al. Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE: A Potential Mimicker of Hepatic Metastases. Clin Nucl Med. 2020. PMID: 32657878. doi:10.1097/RLU.0000000000003192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。